IRIS-Synergy Cohort in the IRIS-DES Registry
Launched by JUNG-MIN AHN · Mar 22, 2016
Trial Information
Current as of July 21, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The IRIS-Synergy study is looking at how well a specific heart stent called the Synergy stent works compared to other similar stents that release medication. This study is important for understanding the safety and effectiveness of the Synergy stent for patients with coronary artery disease, a condition where the blood vessels that supply the heart become narrow or blocked.
To be eligible for this trial, participants need to be at least 19 years old and agree to take part by signing a consent form. However, people who are already receiving the Synergy stent along with another type of stent, those with a very short life expectancy, or those in severe heart failure (known as cardiac shock) cannot join. While the study is currently active, it is not recruiting new participants at this time. If someone qualifies and participates, they can expect to receive care and monitoring related to their stent treatment, helping researchers gather important information to improve heart care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 19 and more
- • Intervention with Synergy stent
- • Agreed with written informed consent form
- Exclusion Criteria:
- • Intervention with Synergy stent and other drug eluting stent at the same time
- • Life expectancy of 1year and under
- • Cardiac shock
About Jung Min Ahn
Jung-Min Ahn is an experienced clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative study designs and robust methodologies. With a focus on ethical standards and regulatory compliance, Jung-Min Ahn leverages a deep understanding of clinical protocols to facilitate the efficient execution of trials across various therapeutic areas. Committed to collaboration with healthcare professionals and stakeholders, the organization aims to translate scientific discoveries into effective treatments, ultimately enhancing the quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Daegu, , Korea, Republic Of
Busan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Kwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Busan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Gangneung, , Korea, Republic Of
Chuncheon, , Korea, Republic Of
Incheon, , Korea, Republic Of
Busan, , Korea, Republic Of
Cheonan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Bucheon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Seongnam, , Korea, Republic Of
Wonju, , Korea, Republic Of
Chuncheon, , Korea, Republic Of
Incheon, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Jeju, , Korea, Republic Of
Seongnam, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials